- Email: [email protected]
Exam 3: American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus
March 2011
CME ACTIVITY
e13
Exam 3: American Gastroenterological Association Technical Review on the Management of Barrett’s Esophagus Test ID No.: gastro00141
Contact hours: 1.0
Expiration Date: March 31, 2012
Question 1: What is the current definition of Barrett esophagus?
a. Metaplastic columnar epithelium within the esophagus. b. Metaplastic columnar epithelium of at least 3 cm of the distal esophagus. c. Intestinal metaplasia within the esophagus. d. Intestinal metaplasia associated with endoscopic visualization of columnar-appearing mucosa.
Question 2: What is the annual risk of esophageal cancer for the general population of patients with Barrett’s esophagus?
a. b. c. d.
4% 2% 1% 0.5%
Question 3: In which of the following would screening to detect Barrett’s esophagus be recommended?
a. 60-year-old White woman with heartburn for 5 years. b. 40-year-old African American man with heartburn for 5 years. c. 60-year-old White man with heartburn for 5 years. d. 35-year-old Latino man with heartburn for 5 years.
Question 4: Surveillance has been associated with reduced mortality from esophageal adenocarcinoma through the following types of studies:
a. b. c. d.
Randomized clinical trials. Prospective parallel cohort studies. Case-control studies. Expert opinion.
a. b. c. d.
Narrow band imaging. White light endoscopy. Chromoendoscopy. Optical coherence tomography.
a. b. c. d. e.
Double-dose proton pump inhibitor. Low-dose aspirin. Selective COX2 inhibitor. Surgical fundoplication. None of the above.
a. b. c. d.
Barrett’s esophagus without dysplasia. Barrett’s esophagus with low-grade dysplasia. Barrett’s esophagus with high-grade dysplasia. Barrett’s esophagus with visible lesions (ulcer, mass) with invasive cancer.
Question 5: Which of the following is recommended for surveillance among patients diagnosed with Barrett’s esophagus?
Question 6: Which of the following is recommended to reduce mortality from esophageal adenocarcinoma?
Question 7: In which of the following scenarios is endoscopic ablation treatment recommended?
CME ACTIVITY
e13
Exam 3: American Gastroenterological Association Technical Review on the Management of Barrett’s Esophagus Test ID No.: gastro00141
Contact hours: 1.0
Expiration Date: March 31, 2012
Question 1: What is the current definition of Barrett esophagus?
a. Metaplastic columnar epithelium within the esophagus. b. Metaplastic columnar epithelium of at least 3 cm of the distal esophagus. c. Intestinal metaplasia within the esophagus. d. Intestinal metaplasia associated with endoscopic visualization of columnar-appearing mucosa.
Question 2: What is the annual risk of esophageal cancer for the general population of patients with Barrett’s esophagus?
a. b. c. d.
4% 2% 1% 0.5%
Question 3: In which of the following would screening to detect Barrett’s esophagus be recommended?
a. 60-year-old White woman with heartburn for 5 years. b. 40-year-old African American man with heartburn for 5 years. c. 60-year-old White man with heartburn for 5 years. d. 35-year-old Latino man with heartburn for 5 years.
Question 4: Surveillance has been associated with reduced mortality from esophageal adenocarcinoma through the following types of studies:
a. b. c. d.
Randomized clinical trials. Prospective parallel cohort studies. Case-control studies. Expert opinion.
a. b. c. d.
Narrow band imaging. White light endoscopy. Chromoendoscopy. Optical coherence tomography.
a. b. c. d. e.
Double-dose proton pump inhibitor. Low-dose aspirin. Selective COX2 inhibitor. Surgical fundoplication. None of the above.
a. b. c. d.
Barrett’s esophagus without dysplasia. Barrett’s esophagus with low-grade dysplasia. Barrett’s esophagus with high-grade dysplasia. Barrett’s esophagus with visible lesions (ulcer, mass) with invasive cancer.
Question 5: Which of the following is recommended for surveillance among patients diagnosed with Barrett’s esophagus?
Question 6: Which of the following is recommended to reduce mortality from esophageal adenocarcinoma?
Question 7: In which of the following scenarios is endoscopic ablation treatment recommended?